Group 1 - The company reported a revenue of 227 million yuan for the first half of 2025, representing a year-on-year growth of 11.50% [1] - The net profit attributable to shareholders of the listed company was 9.48 million yuan, a year-on-year decrease of 35.23% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1.04 million yuan, a year-on-year decrease of 84.63% [1] - The basic earnings per share were 0.16 yuan [1]

证券代码：301097 证券简称：天益医疗 公告编号：2025-044 宁波天益医疗器械股份有限公司 2025 年半年度募集资金存放与使用情况专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司募集资金监管规则》（证监会公告 〔2025〕10 号）和深圳证券交易所印发的《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作（2025 年修订）》（深证上〔2025〕 481 号）的规定，将本公司募集资金 2025 年半年度存放与使用情况专项说明如 下。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意宁波天益医疗器械股份有限公司首 次公开发行股票注册的批复》（证监许可〔2021〕3939 号），本公司由主承销 商国泰君安证券股份有限公司采用余额包销方式，向社会公众公开发行人民币普 通股（A 股）股票 1,473.68 万股，发行价为每股人民币 52.37 元，共计募集资 金 77,176.84 万元，坐扣承销和保荐费用 5,916.93 万元后的募集资 ...

一、监事会会议召开情况 2025年8月27日，宁波天益医疗器械股份有限公司（"公司"）第三届监事会 第二十一次会议在公司会议室召开。本次会议由陈云俊主持。应出席监事3名， 亲自出席监事3名。符合《公司章程》规定的法定人数，本次监事会会议决议合 法有效。 证券代码：301097 证券简称：天益医疗 公告编号：2025-041 宁波天益医疗器械股份有限公司 第三届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、监事会会议审议情况 经与会监事审议表决，一致通过如下议案： 1、审议通过了《关于公司<2025年半年度报告及其摘要>的议案》 监事会认为：董事会编制和审核公司2025年半年度报告及其摘要的内容真实、 准确、完整地反映了公司2025年半年度经营的实际情况，不存在虚假记载、误导 性陈述或者重大遗漏；报告的编制和审核程序符合法律、行政法规的要求，符合 中国证监会及深圳证券交易所的相关规定。 具体内容详见同日在中国证监会指定创业板信息披露网站巨潮资讯网上发 布的相关公告。 表决结果：3票同意、0票反对、0票弃权，0票回避表决。 本议 ...

证券代码：301097 证券简称：天益医疗 公告编号：2025-040 宁波天益医疗器械股份有限公司 第三届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 二、董事会会议审议情况 经与会董事审议表决，一致通过如下议案： 1、审议通过了《关于公司<2025 年半年度报告及其摘要>的议案》 公司董事会在全面审核公司 2025 年半年度报告全文及其摘要后，认为公司 2025 年半年度报告及其摘要的内容真实、准确、完整地反映了公司 2025 年半年 度经营的实际情况，不存在虚假记载、误导性陈述或者重大遗漏；报告的编制和 审核程序符合法律、行政法规的要求，符合中国证监会及深圳证券交易所的相关 规定，同意对外报出。 本议案已经公司第三届董事会审计委员会 2025 年第三次会议审议通过。 具体内容详见同日在中国证监会指定创业板信息披露网站巨潮资讯网上发 布的相关公告。 表决结果：7 票同意、0 票反对、0 票弃权，0 票回避表决。 本议案无需提交公司股东会审议。 2、审议通过了《关于公司<2025 年半年度募集资金存放与 ...

宁波天益医疗器械股份有限公司 2025 年半年度报告全文 宁波天益医疗器械股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 宁波天益医疗器械股份有限公司 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 2025 年半年度报告 2025-042 2025 年 8 月 公司负责人吴志敏、主管会计工作负责人邵科杰及会计机构负责人(会计 主管人员)邵科杰声明：保证本半年度报告中财务报告的真实、准确、完整。 1 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第二节 | 公司简介和主要财务指标 8 | | | --- | --- | --- | | 第三节 | 管理层讨论与分析 11 | | | 第四节 | 公司治理、环境和社会 43 | | | 第五节 | 重要事项 | 47 | | 第六节 | 股份变动及股东情况 | 55 | | 第七节 | 债券相关情况 | 61 | | 第八节 | 财务报告 | 62 | 宁波天益医疗器械股份有限公司 2025 年半年度报 ...

Group 1 - The latest stock price of Tianyi Medical is 47.38 yuan, an increase of 2.20% compared to the previous trading day [1] - The stock opened at 46.24 yuan, reached a high of 48.17 yuan, and a low of 45.64 yuan, with a trading volume of 7,191 hands and a transaction amount of 0.34 billion yuan [1] - Tianyi Medical's main business includes the research, production, and sales of medical devices, covering multiple medical fields such as extracorporeal circulation and blood purification equipment [1] Group 2 - The company has a complete industrial chain layout as a medical enterprise in the Zhejiang region [1] - On the day of reporting, the net outflow of main funds for Tianyi Medical was 665,600 yuan, with a cumulative net outflow of 12.48 million yuan over the past five trading days [1] - The current total market value of the company is 2.793 billion yuan, and the circulating market value is 869 million yuan [1]

Core Insights - The report highlights the significant role of CFOs in listed companies, with the total compensation for A-share CFOs reaching 4.27 billion yuan in 2024, averaging 814,800 yuan per year [1][2] Group 1: CFO Compensation Overview - The average annual salary for CFOs in the A-share medical device sector is 908,600 yuan [2] - The distribution of CFO salaries shows that 24% earn below 500,000 yuan, 42% earn between 500,000 and 1 million yuan, 29% earn between 1 million and 2 million yuan, and 5% earn above 2 million yuan [2] - The top three highest-paid CFOs are Dai Zhenhua from Huatai Medical at 2.70 million yuan, Rui Chenwei from Nanwei Medical at 2.65 million yuan, and Wu Jinhong from Guoke Hengtai at 1.77 million yuan [2] Group 2: CFO Demographics - The age distribution of CFOs shows that those aged 40-50 make up 57%, while 32% are over 50, and 11% are 40 or younger [1] - The youngest CFO is 31 years old, while the oldest is 60 years old [1] - In terms of educational background, 16% of CFOs have an associate degree, 66% hold a bachelor's degree, 16% have a master's degree, and only 2% possess a doctoral degree [1] Group 3: Salary Changes - Among CFOs with over two years of tenure, the largest salary decrease was observed for Kong Xiangqian from Aidi Te, with a decline of 16.86% year-on-year [2] - Conversely, the largest salary increase was for Song Yizhao from Shandong Glass, with a rise of 144.86% year-on-year [2]

Group 1 - Beijing Tianyi Medical Equipment Co., Ltd. has been established with a registered capital of 10 million yuan [1] - The company is involved in the production and sales of various medical devices, including Class I and Class II medical devices, as well as non-medical masks [1] - The business scope also includes manufacturing and sales of plastic and rubber products, metal products, general equipment, and chemical products [1] Group 2 - The company is fully owned by Tianyi Medical, indicating a centralized ownership structure [1] - The company is permitted to engage in the production and sales of Class II and Class III medical devices, as well as disinfection equipment, subject to regulatory approval [1] - The operational activities are conducted in accordance with the business license and relevant regulatory approvals [1]

Core Viewpoint - The medical device industry experienced a slight increase of 0.47% on July 28, with a net outflow of funds amounting to 295 million [1] Group 1: Market Performance - A total of 52 stocks in the sector rose, while 68 stocks declined [1] - The top-performing stocks included: - Aidi Te (16.88%) - Kehua Bio (10.01%) - Rejing Bio (6.88%) - Zhengchuan Co. (6.68%) - David Medical (6.55%) [1][1][1] Group 2: Fund Flow - The net capital flow for the top gainers was as follows: - Aidi Te: 106 million - Kehua Bio: 12 million - Rejing Bio: 21 million - Zhengchuan Co.: -14 million (outflow) [1][1][1] - Other notable stocks with positive fund flow included: - David Medical: -6 million (outflow) - Sainuo Medical: 6 million [1][1] Group 3: Declining Stocks - The stocks with the largest declines included: - Aohua Endoscopy (-4.09%) - Tianyi Medical (-2.73%) - Mountain Outside Mountain (-2.53%) - Ruimaite (-2.42%) - Jianfan Bio (-2.32%) [1][1][1] - Additional stocks that saw declines were: - Lude Medical (-2.22%) - Nanwei Medical (-2.14%) - San Nuo Bio (-2.13%) [1][1]

Summary of Key Points Core Viewpoint - Tianyi Medical (301097) has shown a significant increase in stock price, closing at 48.4 yuan on July 25, 2025, with a rise of 4.85% [1] Financial Performance - The company reported a main revenue of 98.51 million yuan in Q1 2025, reflecting a year-on-year increase of 1.65% [5] - The net profit attributable to shareholders was 4.88 million yuan, a decrease of 9.81% year-on-year [5] - The company experienced a negative non-recurring net profit of -520,700 yuan, down 123.38% year-on-year [5] - The gross profit margin stood at 33.25% [5] Market Activity - On July 25, 2025, the net inflow of main funds was 4.05 million yuan, accounting for 2.98% of the total transaction amount [1][2] - Retail investors contributed a net inflow of 3.07 million yuan, representing 2.26% of the total transaction amount [1][2] - The stock had a turnover rate of 15.33% on the same day, with a total transaction volume of 28,100 hands and a transaction amount of 136 million yuan [1] Financing and Margin Trading - On July 25, 2025, the financing balance was 39.70 million yuan, with a net financing purchase of 1.70 million yuan [3] - There were no shares sold or repaid in the margin trading segment, indicating no activity in this area [3] Industry Comparison - Tianyi Medical's total market value is 2.853 billion yuan, significantly lower than the industry average of 11.518 billion yuan [5] - The company's net asset value is 1.194 billion yuan, compared to the industry average of 3.919 billion yuan [5] - The price-to-earnings ratio (P/E) is 146.28, which is considerably higher than the industry average of 63.28 [5] - The net profit margin of 4.95% is below the industry average of 10.86% [5]